ROCHESTER, Minn. -- A new breast cancer risk prediction model combining histologic features of biopsied breast tissue from women with benign breast disease and individual patient demographic information more accurately classified breast cancer risk than the current screening standard. Results of a Mayo Clinic study comparing the new model to the current standard, the Breast Cancer Risk Assessment Tool (BCRAT), are published in the Journal of Clinical Oncology.
MULTIMEDIA ALERT: Video and audio are available for download on the Mayo Clinic News Network.
"Physicians routinely perform biopsies to evaluate concerning findings in the breast, either felt on exam or seen on mammogram, for the presence of a breast cancer," says Amy Degnim, M.D., a surgeon at Mayo Clinic and a senior author of the study. "However, about three-quarters of these biopsies prove to be benign and are referred to as benign breast disease (BBD)." Annually, more than a million American women have a biopsy with a benign finding and are left wondering if they will later develop breast cancer.
Dr. Degnim and her colleagues hypothesized that certain breast tissue findings, while benign, could help predict which women were at increased risk of developing breast cancer later. "Our new model more accurately classifies a woman's breast cancer risk after a benign biopsy than the BCRAT," Dr. Degnim says. Developed by the National Cancer Institute and the National Surgical Adjuvant Breast and Bowel Project, BCRAT is currently the most commonly used model for predicting breast cancer risk in women with BBD.
To test the new model, Dr. Degnim and her colleagues studied a cohort of approximately 10,000 women who had benign breast biopsies at Mayo Clinic and who received long-term follow-up for a later breast cancer occurrence. Using this cohort, researchers determined the age-specific incidence of breast cancer and death, and combined these estimates with a relative risk model derived from 377 patients who later developed breast cancer and 734 matched controls sampled from the Mayo Clinic BBD cohort. They validated the model using an independent set of women from the Mayo BBD cohort (378 patients with a later breast cancer and 728 matched controls) and compared the risk predictions from the new model with those from the BCRAT.
The concordance statistic from the new model was 0.665 in the model development series and 0.629 in the validation series; these values were higher than those from the BCRAT (0.567 and 0.472, respectively). The BCRAT significantly underpredicted breast cancer risk after benign biopsy (P .004), whereas predictions derived from the new model were appropriately calibrated to observed cancers (P .247).
"Since women with benign breast disease are at higher risk for breast cancer, optimal early detection is extremely important," Dr. Degnim says. "Ideally, women at increased risk for breast cancer should be identified so that we can offer appropriate surveillance and prevention strategies. Unfortunately, the BCRAT risk prediction model does not provide accurate estimates of risk for these women at the individual level."
Co-authors include Lynn Hartmann, M.D., Ryan Frank, Marlene Frost, Ph.D., Daniel Visscher M.D., Robert Vierkant, Tina Hieken, M.D., Karthik Ghosh, M.D., Celine Vachon, Ph.D., and Derek Radisky, Ph.D., all of Mayo Clinic.
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 1-855-776-0015 (toll-free).
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://mayocl.